pharma · Chronic Spontaneous Urticaria · Asthma
Novartis India
Novartis Pharmaceuticals
Novartis Pharmaceuticals is a pharma organization headquartered in CN. Primary therapeutic focus areas include Chronic Spontaneous Urticaria, Asthma, Systemic Lupus Erythematosus, Breast Cancer, Multiple Sclerosis. NovaP
Company details
- Status
- Public
- HQ
- Mumbai, IN
- Founded
- 1996
- Employees
- 2,240
- Programs
- 341
- Drugs
- 317
- Patents
- 0
CLTP001A12202
Phase 2 · small molecule · Part A: Healthy volunteers (Part A is not applicable to the EU; for information only) Part B: pulmonary arterial hypertension
CLTP001A12202 for Part A: Healthy volunteers (Part A is not applicable to the EU; for information only) Part B: pulmonary arterial hypertension is a Phase 2 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code CLTP001A12202
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Part A: Healthy volunteers (Part A is not applicable to the EU; for information only) Part B: pulmonary arterial hypertension
- Status
- active
- Trials
- 1